MTOR and neoplasm: CSNK1G2 selectively manipulates the tumor progress, sometimes in a nuclear and genomic manner via ERE inhibition of specific genes associated with tumor growth, but sometimes by non-genomic manner via the AKT/mTOR/S6K pathway, followed by p-ER167 activity.